Astrazeneca moves new global head office to cambridge


Astrazeneca moves new global head office to cambridge

AstraZeneca has announced it is opening its new corporate headquarters and global research and development center at the Cambridge Biomedical Campus, Cambridge, UK. The site will be ready by 2016, where 2,000 office and research & development staff will work.

The company announced in March this year that it was investing UK£330 million (US$511 million) on a facility in Cambridge as part of its strategy to create global research and development centers in the UK, USA and Sweden.

AstraZeneca's small molecule and biologics R&D activity will be brought together at the purpose-built Cambridge site. MedImmune, AstraZeneca's biologics arm, will also have its biologics research and protein engineering R&D laboratories located at Cambridge. MedImmune already has 500 employees at Granta Park, to the south east of Cambridge.

AstraZeneca says its largest center for oncology (cancer) research will be located at the new site, as well as R&D on several other medial areas, including conditions of the central nervous system, autoimmune diseases, inflammation, respiratory conditions, and cardiovascular and metabolic diseases.

A number of the company's pre-clinical research capabilities will be housed at the new facility, as will medicinal chemistry and high-throughput screening.

AstraZeneca added that "Other global functions will join the research and development teams at the new facility and Cambridge will become AstraZeneca's corporate headquarters."

The Cambridge Biomedical Campus site

The Cambridge Biomedical Campus' 70-acre site is home to several healthcare, research and academic organizations, including:
  • The University of Cambridge School of Clinical Medicine
  • Addenbrooke's Hospital
  • The Medical Research Council (MRC) Laboratory of Molecular Biology
  • The Wellcome Trust-MRC Institute of Metabolic Science
  • The Cancer Research UK Cambridge Institute
AstraZeneca's new global headquarters and R&D centers will occupy approximately 11 acres.

Pascal Soriot, Chief Executive Officer of AstraZeneca said:

"Cambridge competes on the global stage as a respected innovation hub for life sciences and our choice of site puts us at the heart of this important ecosystem, providing valuable collaboration opportunities. Moving to the Cambridge Biomedical Campus means our people will be able to rub shoulders with some of the world's best scientists and clinicians carrying out some of the world's leading research - that's a really exciting prospect. We hope that our move will contribute to the growing success of Cambridge.

Today's announcement also confirms AstraZeneca's long-standing commitment to the UK and increases the chances that the next generation of medicines will be discovered here in Britain."

David Willetts MP (Member of Parliament), Minister for Universities and Science at the Department for Business, Innovation and Skills, said: "AstraZeneca's investment is excellent news for the UK life sciences industry. It strengthens our global competitiveness and supports our aim of making the UK the best place in the world for the discovery and commercialisation of medical innovations. These are key themes of the Government's life sciences strategy."

Professor Sir Leszek Borysiewicz FRS, Vice-Chancellor of the University of Cambridge, said:

"I am delighted with AstraZeneca's choice. It is a measure of the world-class environment that Cambridge offers to knowledge-based industries and it reflects AstraZeneca's commitment to making new discoveries. Over 1,500 companies in the Cambridge cluster of high-tech industries have found that proximity - to the University, to our NHS partners, and to each other - enables productive relationships and stimulates competition. As a global player, AstraZeneca will add tremendously to that environment and we look forward to the creative collaborations that will surely follow."

About AstraZeneca

In 2012, AstraZeneca PLC was the sixth-largest pharmaceutical company in the world, based on sales at ex-manufacture levels. Below is a list of the top nine (2012, source: IMS Health):
  • 1 - Novartis
  • 2 - Pfizer
  • 3 - Merck & Co
  • 4 - Sanofi
  • 5 - Roche
  • 6 - AstraZeneca
  • 7 - Johnson & Johnson
  • 8 - Abbott
  • 9 - Teva
Astra-Zeneca is a British-Swedish company headquartered in the United Kingdom, and operates in more than 100 countries.

AstraZeneca employs about 51,700 people worldwide:

  • 46% in Europe
  • 28% in the Americas
  • 26.5% in Asia-Pacific
The company's portfolio of drugs cover several disease areas, including inflammation, respiratory, neuroscience, infection, gastrointestinal, cardiovascular and cancer.

AstraZeneca was founded in 1999 when the Swedish company Astra AB merged with the British company Zeneca Group.

AstraZeneca has a primary listing on the LSE (London Stock Exchange) and is one of the companies listed in the FTSE 100 index. Its shares are also traded in the New York and Stockholm Stock Exchanges. According to the Financial Times (June 19th, 2013), the company has a market capitalization of £40.9 billion ($63.34 billion).

AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK (Video Medical And Professional 2020).

Section Issues On Medicine: Medical practice